Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 disease on placental histopathology. PLAXAVID study

  • Montáns Araújo, José
  • García Ruiz, Itziar
  • Garcia Aguilar, E.
  • Hidalgo Bermejo, F. J.
  • Suy Franch, Anna
  • Maiz, Nerea
COVID-19 disease; Placental histopathology, Malaltia COVID-19; Histopatologia placentària, Enfermedad COVID-19; Histopatología placentaria, Background: The impact of COVID-19 on pregnancy has been analyzed suggesting an increased risk of placental lesions that might lead to maternal and neonatal complications. However, the current published evidence is not conclusive because contradictory results. Methods: PLAXAVID is an observational, retrospective, histopathological, single-center study that aimed to evaluate the prevalence of vascular and inflammatory lesions in placental and umbilical cord samples of one hundred women infected by SARS-CoV-2 during pregnancy. Results: The histopathological analysis showed that in most of the placentas (77.8%) there were signs of maternal vascular malperfusion (MVM; primary endpoint). The most common MVM features were an accelerated villous maturation (37.4%), central villous infarcts (33.3%), and villous agglutination (46.5%). Fetal vascular malperfusion (FVM) was identified in 57.6% of samples, and the most frequent features were hyalinized avascular villi (38.4%), fetal vascular thrombi (20.2%) and umbilical cord at risk of partial obstruction (14.1%). Acute and chronic inflammatory pathology were noticed in 22.2% and 49.5% of placentas, respectively. No significant correlations were found between MVM presence and the time, duration, and severity of infection, nor with the duration of pregnancy. However, in critically ill patients, the pregnancy duration (p=0.008), newborn weight (p=0.003), and APGAR test scores (p<0.001) were significantly lower. The same trend was observed considering the presence of infection at the time of delivery and in preterm births. Conclusion: A very high percentage of placentas with vascular and/or inflammatory lesions was found in the analyzed cohort. Therefore, PLAXAVID study results supported that COVID-19 should be considered a risk factor during gestation and requires close monitoring of pregnancy., The study has been founded by ITF Research Pharma S.L.U. The Gesta-COVID19 was supported by a grant from Instituto de Salud Carlos III (ISCIII) (COV20/00188).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gestation and COVID-19, clinical and microbiological observational study (Gesta-COVID19)

  • Suy, Anna|||0000-0003-2987-6105
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Carbonell-Socias, Melchor|||0000-0002-8165-6751
  • García Manau, Pablo|||0000-0002-2415-1626
  • Rodó, Carlota|||0000-0001-8801-5677
  • Maiz, Nerea|||0000-0001-8261-6383
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernández Hidalgo, Nuria|||0000-0002-2115-344X
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Camba, Fatima
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Carreras Moratonas, Elena|||0000-0003-3471-7248
The Coronavirus Disease 2019 (COVID-19) is a novel disease which has been having a worldwide affect since December 2019. Evidence regarding the effects of SARS-CoV-2 during pregnancy is conflicting. The presence of SARS-CoV-2 has been demonstrated in biological samples during pregnancy (placenta, umbilical cord or amniotic fluid); however, maternal and fetal effects of the virus are not well known. Descriptive, multicentre, longitudinal, observational study in eight tertiary care hospitals throughout Spain, that are referral centres for pregnant women with COVID-19. All pregnant women with positive SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction during their pregnancy or 14 days preconception and newborns born to mothers infected with SARS-CoV-2 will be included. They will continue to be followed up until 4 weeks after delivery. The aim of the study is to investigate both the effect of COVID-19 on the pregnancy, and the effect of the pregnancy status with the evolution of the SARS-CoV-2 disease. Other samples (faeces, urine, serum, amniotic fluid, cord and peripheral blood, placenta and breastmilk) will be collected in order to analyse whether or not there is a risk of vertical transmission and to describe the behaviour of the virus in other fluids. Neonates will be followed until 6 months after delivery to establish the rate of neonatal transmission. We aim to include 150 pregnant women and their babies. Ethics approval will be obtained from all the participating centres. There is little information known about COVID-19 and its unknown effects on pregnancy. This study will collect a large number of samples in pregnant women which will allow us to demonstrate the behaviour of the virus in pregnancy and postpartum in a representative cohort of the Spanish population.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 disease on placental histopathology. PLAXAVID study

  • Montáns Araújo, José
  • García Ruiz, Itziar
  • Garcia Aguilar, E.
  • Hidalgo Bermejo, F. J.
  • Suy Franch, Anna
  • Maiz, Nerea
COVID-19 disease; Placental histopathology, Malaltia COVID-19; Histopatologia placentària, Enfermedad COVID-19; Histopatología placentaria, Background: The impact of COVID-19 on pregnancy has been analyzed suggesting an increased risk of placental lesions that might lead to maternal and neonatal complications. However, the current published evidence is not conclusive because contradictory results. Methods: PLAXAVID is an observational, retrospective, histopathological, single-center study that aimed to evaluate the prevalence of vascular and inflammatory lesions in placental and umbilical cord samples of one hundred women infected by SARS-CoV-2 during pregnancy. Results: The histopathological analysis showed that in most of the placentas (77.8%) there were signs of maternal vascular malperfusion (MVM; primary endpoint). The most common MVM features were an accelerated villous maturation (37.4%), central villous infarcts (33.3%), and villous agglutination (46.5%). Fetal vascular malperfusion (FVM) was identified in 57.6% of samples, and the most frequent features were hyalinized avascular villi (38.4%), fetal vascular thrombi (20.2%) and umbilical cord at risk of partial obstruction (14.1%). Acute and chronic inflammatory pathology were noticed in 22.2% and 49.5% of placentas, respectively. No significant correlations were found between MVM presence and the time, duration, and severity of infection, nor with the duration of pregnancy. However, in critically ill patients, the pregnancy duration (p=0.008), newborn weight (p=0.003), and APGAR test scores (p<0.001) were significantly lower. The same trend was observed considering the presence of infection at the time of delivery and in preterm births. Conclusion: A very high percentage of placentas with vascular and/or inflammatory lesions was found in the analyzed cohort. Therefore, PLAXAVID study results supported that COVID-19 should be considered a risk factor during gestation and requires close monitoring of pregnancy., The study has been founded by ITF Research Pharma S.L.U. The Gesta-COVID19 was supported by a grant from Instituto de Salud Carlos III (ISCIII) (COV20/00188).